4D Molecular Therapeutics (FDMT) Free Cash Flow Growth (5y) (2025 - 2026)
4D Molecular Therapeutics (FDMT) Free Cash Flow Growth (5y) (2025 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - |
| 4 | BeOne Medicines | 468.98 Bn | 464.19 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.24 Bn | 115.99 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.45 Bn | 61.70 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.04 Bn | 63.04 Bn | - |
| 8 | Argenx Se | 55.79 Bn | 50.60 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.79 Bn | 34.78 Bn | 959.66 Mn |
| 10 | 4D Molecular Therapeutics | 703.11 Mn | 312.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.43% |
| Dec 31, 2025 | 27.62% |
| Sep 30, 2025 | -29.00% |
| Jun 30, 2025 | -46.73% |
| Mar 31, 2025 | -28.10% |